Table 3 Epigenetic drugs

DNMT

Azacitidine

√

Chronic myelomonocytic leukemia

–

Myelodysplastic syndrome

–

Decitabine

√

Chronic myelomonocytic leukemia

–

Myelodysplastic syndrome

–

Promoting osteogenesis

SOD2 → ROS↓

[34,35,36]

RG108

–

Improving BMSC migration

TERT, bFGF,

[99]

Delaying BMSC senescence

VEGF, ANG

Guadecitabine

–

cancer therapy possibility

–

IDH1

Ivosidenib

√

Oncometabolite therapy

–

IDH2

Enasidenib

√

Oncometabolite therapy

–

SUV39h1/2

Chaetocin

–

Promoting osteogenesis

Wnt/β–catenin

[41]

EZH2

Tazemetostat

√

Follicular lymphoma

–

DZNep

–

Promoting osteogenesis

Wnt/β–catenin

[42]

GSK126

–

Promoting osteogenesis

BMP2

[43, 44]

Valemetostat

–

Cancer therapy possibility

–

CPI-1205

–

Cancer therapy possibility

–

CPI-0209

–

Cancer therapy possibility

–

KDM5A

JIB-04

–

Promoting osteogenesis

BMP2

[46]

LSD1

Pargyline

√

Decrease blood pressure

–

Promoting Osteogenesis

H3K4

[47]

Iadademstat

–

Acute myelomonocytic leukemia

–

Myelodysplastic syndrome

–

CC-90011

–

Cancer therapy possibility

–

INCB059872

–

Cancer therapy possibility

–

HDAC

I/II

Vorinostat

√

Cutaneous T cell lymphomas

–

Promoting osteogenesis

Runx2, BMP

[50]

Belinostat

√

Peripheral T cell lymphomas

–

Panobinostat

√

Multiple myeloma

–

Romidepsin

√

Cutaneous T cell lymphomas

–

Peripheral T cell lymphomas

–

Chidamide

*

T cell lymphomas

–

TSA

–

Promoting osteogenesis

Runx2, BMP

[49]

Delaying BMSC senescence

NF–κB (p65)

Entinostat

–

Cancer therapy possibility

–

NBM-BMX

–

Cancer therapy possibility

–

Ricolinostat

–

Cancer therapy possibility

–

Mocetinostat

–

–

–

Domatinostat

–

–

–

Pracinostat

–

–

–

OKI-179

–

–

–

Givinostat

–

–

–

Abexinostat

–

–

–

Resminostat

–

–

–

Fimepinostat

–

–

–

Citarinostat

–

–

–

KA2507

–

–

–

HDACIII

Resveratrol

Cartilage protection

SIRT1 → HIF–2α↓

[100,101,102]

BRD4

Molibresib

Birabresib

–

–

NUT midline carcinoma

NUT midline carcinoma

–

–